N.J. biotech seeks to raise $57.5M by going public

09/19/2013 | American City Business Journals · Xconomy

Aerie Pharmaceuticals, a Bedminster, N.J.-based developer of eye disease treatments, could bring in as much as $57.5 million in an initial public offering. The company plans to use the money to create a sales force and advance its experimental glaucoma drug AR-13324 through a Phase III trial and the drug PG324 through a midstage trial.

View Full Article in:

American City Business Journals · Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Teaching Associate (Hospitality Management)
University of Illinois at Urbana-Champaign
Urbana, IL
Director, Global Regulatory Affairs
Rodan and Fields, LLC
San Francisco, CA
Senior Compliance Analyst
ACell, Inc.
Columbia, MD
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA